DDInter1036 DDInter1676
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Lenvatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lenvatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venlafaxine
Lenvatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tipiracil
Lenvatinib {u} may lead to a major life threatening interaction when taken with {v} Vandetanib
Lenvatinib {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Lenvatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Tipiracil
Lenvatinib may lead to a major life threatening interaction when taken with Vandetanib
Lenvatinib may lead to a major life threatening interaction when taken with Ivosidenib